Total Payments
$374,307
2024 Payments
$29,806
Companies
10
Transactions
242
Medicare Patients
963
Medicare Billing
$169,609
Payment Breakdown by Category
Consulting$165,879 (44.3%)
Research$77,133 (20.6%)
Travel$68,411 (18.3%)
Other$54,494 (14.6%)
Education$4,673 (1.2%)
Food & Beverage$3,718 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $165,879 | 54 | 44.3% |
| Unspecified | $77,133 | 35 | 20.6% |
| Travel and Lodging | $68,411 | 65 | 18.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,217 | 41 | 14.0% |
| Education | $4,673 | 2 | 1.2% |
| Food and Beverage | $3,718 | 44 | 1.0% |
| Honoraria | $2,277 | 1 | 0.6% |
Payments by Type
General
$297,174
207 transactions
Research
$77,133
35 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $194,542 | 77 | $0 (2024) |
| PFIZER INC. | $54,897 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $40,099 | 33 | $0 (2023) |
| Novartis Pharma AG | $32,223 | 19 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $24,350 | 39 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $16,620 | 11 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $6,042 | 5 | $0 (2017) |
| ABBVIE INC. | $5,400 | 4 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $111.39 | 1 | $0 (2018) |
| Incyte Corporation | $23.72 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,806 | 17 | Novartis Pharmaceuticals Corporation ($26,386) |
| 2023 | $54,035 | 16 | Novartis Pharmaceuticals Corporation ($44,409) |
| 2022 | $41,182 | 24 | Novartis Pharma AG ($16,313) |
| 2021 | $18,906 | 12 | Novartis Pharmaceuticals Corporation ($9,126) |
| 2020 | $34,440 | 20 | NOVARTIS PHARMACEUTICALS CORPORATION ($14,709) |
| 2019 | $85,016 | 40 | Novartis Pharmaceuticals Corporation ($55,801) |
| 2018 | $54,787 | 70 | Otsuka Pharmaceutical Co., Ltd. ($24,350) |
| 2017 | $56,135 | 43 | Novartis Pharmaceuticals Corporation ($26,406) |
All Payment Transactions
242 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $31.60 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/05/2024 | Novartis Pharma AG | GLEEVEC (Drug) | Food and Beverage | In-kind items and services | $34.21 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 09/28/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $391.86 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,450.43 | Research |
| Study: CABL001AUS08 • Category: Oncology | ||||||
| 06/07/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $795.98 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $563.47 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $397.99 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $126.79 | General |
| 05/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $162.05 | Research |
| Study: CABL001X2101 • Category: ONCOLOGY | ||||||
| 02/16/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 02/08/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $3,451.26 | Research |
| Study: CABL001AUS08 • Category: Oncology | ||||||
| 01/29/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,400.00 | General |
| 01/24/2024 | Novartis Pharma AG | GLEEVEC (Drug), SCEMBLIX | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2023 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/08/2023 | Novartis Pharma AG | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $125.60 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $298.65 | General |
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $185.89 | General |
| 09/06/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $69.51 | General |
| Category: Oncology | ||||||
| 08/01/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $4,351.00 | Research |
| Study: CABL001AUS04 • Category: Oncology | ||||||
| 08/01/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,265.77 | Research |
| Study: CABL001X2101 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SCEMBLIX Study Related Review Article Writing Support | Novartis Pharmaceuticals Corporation | $24,868 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $17,138 | 8 |
| BOSUTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,220 | 12 |
| CABL001AUS08 | Novartis Pharmaceuticals Corporation | $5,258 | 3 |
| CABL001AUS04 | Novartis Pharmaceuticals Corporation | $4,351 | 1 |
| CABL001A2301 | Novartis Pharmaceuticals Corporation | $2,614 | 1 |
| AN OPEN LABEL, MULTI-CENTER PHASE IIIB STUDY OF ASCIMINIB (ABL001) MONOTHERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA ON CHRONIC PHASE (CML-CP) PREVIOUSLY TREATED WITH AT LEAST 2 PRIOR TKIS (TYROSINE KINASE INHIBITORS) | Novartis Pharmaceuticals Corporation | $2,160 | 1 |
| CABL001X2101 | Novartis Pharmaceuticals Corporation | $1,266 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,178 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,073 | 2 |
| CABL001X2101 | Novartis Pharma AG | $553.91 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR SCEMBLIX RESEARCH | Novartis Pharmaceuticals Corporation | $285.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $168.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 305 | 499 | $309,685 | $49,291 |
| 2022 | 6 | 254 | 539 | $266,575 | $43,173 |
| 2021 | 5 | 214 | 475 | $234,465 | $39,567 |
| 2020 | 5 | 190 | 430 | $236,920 | $37,578 |
Total Patients
963
Total Services
1,943
Medicare Billing
$169,609
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 126 | 223 | $162,790 | $27,199 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 126 | $68,670 | $9,666 | 14.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $42,845 | $6,524 | 15.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 38 | $19,760 | $4,059 | 20.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 35 | 71 | $15,620 | $1,844 | 11.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 191 | $100,275 | $17,841 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 115 | 194 | $72,750 | $10,525 | 14.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $40,755 | $6,369 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 36 | $26,640 | $4,646 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 27 | $14,715 | $2,337 | 15.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 18 | 52 | $11,440 | $1,455 | 12.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 175 | $88,375 | $16,695 | 18.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 106 | 223 | $83,625 | $13,118 | 15.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 34 | 34 | $35,530 | $5,376 | 15.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 20 | $14,400 | $2,605 | 18.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 22 | 23 | $12,535 | $1,773 | 14.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 184 | $91,080 | $17,660 | 19.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 71 | 151 | $78,520 | $10,769 | 13.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $25,740 | $3,680 | 14.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 34 | 35 | $24,150 | $3,103 | 12.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 14 | 16 | $11,040 | $1,530 | 13.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 18 | $6,390 | $836.69 | 13.1% |
About Dr. Michael Mauro, MD
Dr. Michael Mauro, MD is a Hematology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609884188.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mauro, MD has received a total of $374,307 in payments from pharmaceutical and medical device companies, with $29,806 received in 2024. These payments were reported across 242 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($165,879).
As a Medicare-enrolled provider, Mauro has provided services to 963 Medicare beneficiaries, totaling 1,943 services with total Medicare billing of $169,609. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location New York, NY
- Active Since 08/03/2006
- Last Updated 04/07/2015
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1609884188
Products in Payments
- SCEMBLIX (Drug) $59,297
- TASIGNA (Drug) $57,409
- BOSULIF (Drug) $54,897
- SPRYCEL (Drug) $29,998
- ICLUSIG (Drug) $29,943
- ABL002 (Drug) $27,143
- KYMRIAH (Biological) $10,070
- KISQALI (Drug) $9,836
- ALUNBRIG (Drug) $6,012
- OPDIVO (Biological) $5,179
- CML (Drug) $5,125
- RYDAPT (Drug) $4,796
- GLEEVEC (Drug) $2,834
- ABL001A (Drug) $286.50
- XARELTO (Drug) $111.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in New York
Dr. Barry Coller, M.d, M.D
Hematology — Payments: $10.2M
Hematology $10.2M
Dr. Dan Douer, M.d, M.D
Hematology — Payments: $665,161
Hematology $665,161
Louis Aledort, Md, MD
Hematology — Payments: $377,491
Hematology $377,491
Faith Davies, Md, MD
Hematology — Payments: $373,421
Hematology $373,421
Ann Jakubowski, Md, MD
Hematology — Payments: $92,726
Hematology $92,726
Maria Palomba, Md, MD
Hematology — Payments: $70,690
Hematology $70,690